We are live on ! Find out more
CMMB

Chemomab Therapeutics
CMMB

14 hedge funds and large institutions have $22.7M invested in Chemomab Therapeutics in 2021 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.01% more ownership

Funds ownership: 0.36% → 0.36% (+0.01%)

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

7% less funds holding

Funds holding: 15 → 14 (-1)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

37% less capital invested

Capital invested by funds: $35.9M → $22.7M (-$13.2M)

Holders
14
Holders Change
-1
Holders Change %
-6.67%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
4
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AIM
ARK Investment Management
Florida
+$770K
2
VF
Virtu Financial
New York
+$199K
3
Morgan Stanley
Morgan Stanley
New York
+$102K
4
GCP
GSA Capital Partners
United Kingdom
+$100K
5
State Street
State Street
Massachusetts
+$19.4K

Top Sellers

Rank Fund Capital Flow
1
Osaic Holdings
Osaic Holdings
Arizona
-$447K
2
IC
Ikarian Capital
Texas
-$177K
3
BFM
Boothbay Fund Management
New York
-$131K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$17.8K
5
SWM
Spire Wealth Management
Virginia
-$6K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$17.8M – – –
AIM
2
ARK Investment Management
Florida
$1.84M +$770K +21,692 +48%
IC
3
Ikarian Capital
Texas
$1.83M -$177K -5,000 -7%
MIH
4
Meitav Investment House
Israel
$259K – – –
State Street
5
State Street
Massachusetts
$226K +$19.4K +546 +7%
BFM
6
Boothbay Fund Management
New York
$198K -$131K -3,702 -34%
VF
7
Virtu Financial
New York
$155K +$199K +5,610 New
AWM
8
Apollon Wealth Management
South Carolina
$83K – – –
Geode Capital Management
9
Geode Capital Management
Massachusetts
$80K -$17.8K -501 -15%
Morgan Stanley
10
Morgan Stanley
New York
$80K +$102K +2,887 +12,029%
GCP
11
GSA Capital Partners
United Kingdom
$78K +$100K +2,819 New
Osaic Holdings
12
Osaic Holdings
Arizona
$31K -$447K -12,607 -92%
YAVAPFMC
13
Yahav Achim Ve Achayot - Provident Funds Management Company
Israel
$21K – – –
UBS Group
14
UBS Group
Switzerland
$13K +$816 +23 +5%
SWM
15
Spire Wealth Management
Virginia
– -$6K -125 Closed
TRCT
16
Tower Research Capital (TRC)
New York
– -$1K -12 Closed

CMMB Hedge Fund Activity: Q4 2021 in Review

14 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q4 2021, worth a combined $22.7M — down 37% from $35.9M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of CMMB and 2 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 4 added.

The largest buyer was ARK Investment Management, adding an estimated $770K. The largest seller was Osaic Holdings, cutting an estimated $447K.

  • 14 institutional investors held Chemomab Therapeutics (CMMB) as of Q4 2021, down from 15 in Q3 2021.
  • Funds reported $22.7M of Chemomab Therapeutics stock for Q4 2021, down 37% quarter-over-quarter.
  • 2 funds opened new Chemomab Therapeutics positions in Q4 2021 and 3 closed out, a net change of -1 holder.
  • The largest Chemomab Therapeutics buyer in Q4 2021 was ARK Investment Management, an estimated $770K added.
  • The largest Chemomab Therapeutics seller in Q4 2021 was Osaic Holdings, an estimated $447K sold.

Based on aggregated 13F filings for Q4 2021.